Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab in Chinese migraine patients
NCT05458011Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2022
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in migraine (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Mean Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose. Started Sep 2022; status: completed.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05458011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05458011.